Evidence map›Paper›PMID 39998071›Full record

ArticleToxins2025

Identification of Potential Therapeutic Targets Against Anthrax-Toxin-Induced Liver and Heart Damage.

Lihong Wu, Yanping Chen, Yongyong Yan, Haiyan Wang, Cynthia D Guy, John Carney, Carla L Moreno, Anaisa Quintanilla-Arteaga, Fernando Monsivais, Zhichao Zheng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lihong WuCenter of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Yanping ChenCenter of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Yongyong YanCenter of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.ORCID 0009-0007-8070-6116
Haiyan WangCenter of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Cynthia D GuyLiver and GI Pathology Section, Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
John CarneyLiver and GI Pathology Section, Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
Carla L MorenoCenter of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Anaisa Quintanilla-ArteagaL. Frederick Francis Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Fernando MonsivaisCenter of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Zhichao ZhengCenter of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Mingtao ZengCenter of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.

Funding

Targeted-delivery of small interference RNA against anthrax (1 R21 AI118228-01A1)R21AI118228 · NIAID · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI ZENG, MINGTAO · 2015 to 2016
$478k
NIAID NIH HHS R21 AI118228NIH HHS 1R21AI118228-02A1
6 · The paper itself

Abstract

Anthrax represents a disease resulting from infection by toxin-secreting bacteria,

Indexed as

Antigens, BacterialBacterial ToxinsChemical and Drug Induced Liver InjuryLiverAnimalsAnthraxApoptosisCell SurvivalHepatocytesMaleMiceMice, Inbred C57BLMice, KnockoutMyocytes, Cardiacanthrax toxinAntigens, BacterialBacterial Toxinsanthrax edema toxinanthrax lethal toxinBacillus anthraciscardiomyocyteshepatocytesmicroarrayorgan damageplasminogen activator inhibitor 1small interfering RNAtherapeutic targets

Identifiers

PMID39998071
PMCPMC11861023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.